Acrux developed Lenzetto® (estradiol 1.53 mg/spray, transdermal spray, solution), a novel estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause.
The spray applied is clear, generally dries in less than two minutes and has a low incidence of reported skin irritation. Clinical studies have shown that Lenzetto® is absorbed through the skin and provides efficacious serum concentrations for the treatment of vasomotor symptoms in postmenopausal women.
Acrux licenced Lenzetto® to Gedeon Richter to commercialise it in the European Union. Lenzetto® was launched in 2016 and is now sold in over 30 countries across the European Union and other markets in South America.